Abstract
Bioactive peptides are generally synthesized within large precursor molecules, from which the active moiety must be enzymatically excised by one or more specific peptidases (1). For most peptides, this processing occurs intracellularly, within the secretory pathway, but cosecretory or extracellular processing can also occur. Peptidases also play a critical role in the termination of peptide signals, via cleavage to inactive fragments (2,3). The characterization of the peptidases involved in the generation and metabolism of peptides is thus of critical importance to the understanding of the physiology of specific peptide hormones and neurotransmitters.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Docherty, K. and Steiner, D. F. (1982) Post-translational proteolysis in polypeptide hormone biosynthesis. Ann. Rev. Physiol. 44, 625–638.
Turner, A. J. and Barnes, K. (1994) Neuropeptidases: candidate enzymes and techniques for study. Biochem. Soc. Trans. 22, 122–127.
Schwartz, J.-C, Malfroy, B., and de la Baume, S. (1981) Biological inactivation of enkephalins and the role of enkephalin-dipeptidyl-carboxypeptidase (“enkephalinase”) as neuropeptidase. Life Sci. 29, 1715–1740.
Chu, T. G. and Orlowski, M. (1984) Active site directed N-carboxymethyl peptide inhibitors of a soluble metalloendopeptidase from rat brain. Biochemistry 23, 3598–3603.
Shrimpton, C. N., Abbenante, G., Lew, R. A., and Smith, A. I. (2000) Development and characterisation of novel potent and stable inhibitors of endopeptidase EC 34.24.15. Biochem. J. 345, 351–356.
Vincent, B., Jiracek, J., Noble, F., et al. (1997) Effect of a novel selective and potent phosphinic peptide inhibitor of endopeptidase 34.24.16 on neurotensin-induced analgesia and neuronal inactivation. Brit. J. Pharmacol. 121, 705–710.
Jiracek, J., Yiotakis, A., Vincent, B., et al. (1995) Development of highly potent and selective phosphinic peptide inhibitors of zinc endopeptidase 24.15 using combinatorial chemistry. J. Biol. Chem. 270, 21,701–21,706.
Dauch, P., Vincent, J.-P., and Checler, F. (1991) Specific inhibition of endopeptidase 24.16 by dipeptides. Eur. J. Biochem. 202, 269–276.
Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) Protein measurement surement with the folin phenol reagent. J. Biol. Chem. 193, 265–275.
Skidgel, R. A. (1992) Bradykinin-degrading enzymes: structure, function, distribution, and potential roles in cardiovascular pharmacology. J. Cardiovasc. Pharmacol. 20 (Suppl. 9), S4–S9.
Hoang, M. V. and Turner, A. J. (1997) Novel activity of endothelin-converting enzyme: hydrolysis of bradykinin. Biochem. J. 327, 23–26.
Smith, A. I. and Lew, R. A. (1995) The combination of high performance liquid chromatography and radioimmunoassay for the characterization of peptide processing pathways, in Peptidases and Neuropeptide Processing (Smith, A. I., ed.), Academic, San Diego, CA, pp. 125–139.
Campbell, D. J., Kladis, A., and Duncan, A.-M. (1993) Nephrectomy, converting enzyme inhibition and angiotensin peptides. Hypertension 22, 513–522.
Campbell, D. J., Kladis, A., and Duncan, A.-M. (1993) Bradykinin peptides in kidney, blood, and other tissues of the rat. Hypertension 21, 155–165.
Lawrence, A. C., Evin, G., Kladis, A., and Campbell, D. J. (1990) An alternative strategy for the radioimmunoassay of angiotensin peptides using amino-terminal-directed antisera: measurement of eight angiotensin peptides in human plasma. . J. Hypertension 8, 715–724.
Dean, R., Murone, C., Lew, R. A., et al. (1997) Localization of bradykinin B2 binding sites in rat kidney following chronic ACE inhibitor treatment. Kidney Int. 52, 1261–1270.
Lew, R. A., Tomoda, F., Evans, R. G., et al. (1996) Synthetic inhibitors of endopeptidase EC 3.4.24.15: potency and stability in vitro and in vivo. Brit. J. Pharmacol. 118, 1269–1277.
Smith, A. I., Lew, R. A., Shrimpton, C. N., Evans, R. G., and Abbenante, G. (2000) A novel stable inhibitor of endopeptidases EC 3.4.24.15 and 3.4.24.16 potentiates bradykinin-induced hypotension. Hypertension 35, 626–630.
Telford, S. E., Smith, A. I., Lew, R. A., Perich, R. B., Madden, A. C, and Evans, R. G. (1995) Role of angiotensin converting enzyme in the vascular effects of an endopeptidase 24.15 inhibitor. Br. J. Pharmacol. 114, 1185–1192.
Moeller I., Lew, R. A., Albiston, A. L., Mendelsohn, F A. O., and Chai, S.-Y. (1999) A globin fragment, LVV-hemorphin-7, induces [3H]thymidine incorporation in a neuronal cell line via the AT4 receptor. J. Neurochem. 73, 301–308.
Lew, R. A., Tetaz, T, and Smith, A. I. (1994) Characterization of a membrane-associated EC 3.4.24.15-like endopeptidase expressed by endothelial cells of the ovine median eminence. J. Neuroendocrinol. 6, 225–232.
Norman, M. U., Smith, A. I., and Lew, R. A. (1999) Role of calcium in the release of the bradykinin-degrading peptidase EC 3.4.24.16 from endothelial cells. Lett. Peptide Sci. 6, 349–352.
Lew, R. A., Boulos, E., Stewart, K. M., et al. (2000) Bradykinin analogs with β-amino acid substitutions reveal subtle differences in substrate specificity between the endopeptidases EC 3.4.24.15 and EC 3.4.24.16. J. Peptide Science 6, 440–445.
Lew, R. A., Hey, N. J., Tetaz, T. J., Glucksman, M. J., Roberts, J. L., and Smith, A. I. (1995) Substrate specificity differences between recombinant rat testes endopeptidase EC 3.4.24.15 and the native brain enzyme. Biochem. Biophys. Res. Comm. 209, 788–795.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Humana Press Inc.
About this protocol
Cite this protocol
Lew, R.A. (2004). HPLC in the Analysis of Peptide Metabolism. In: Aguilar, MI. (eds) HPLC of Peptides and Proteins. Methods in Molecular Biology™, vol 251. Springer, Totowa, NJ. https://doi.org/10.1385/1-59259-742-4:275
Download citation
DOI: https://doi.org/10.1385/1-59259-742-4:275
Publisher Name: Springer, Totowa, NJ
Print ISBN: 978-0-89603-977-3
Online ISBN: 978-1-59259-742-0
eBook Packages: Springer Protocols